← All trials
NCT06868212
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 11, 2025
- Primary completion
- May 11, 2027
- Completion date
- Aug 3, 2027
- First posted
- Mar 10, 2025
- Last posted
- Oct 31, 2025
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovartisLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.